Source: centralcharts

Press Release: Myovant Sciences : Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020

BASEL, Switzerland, March 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating

89/100

Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more